Article
Type I IFNs differentially modulate IL-12p70 production by human dendritic cells depending on the maturation status of the cells and counteract IFN-gamma-mediated signaling.
Clinical immunology (Orlando, Fla.) - 1 Jun 2003
Heystek H C, den Drijver B, Kapsenberg M L, van Lier R A W, de Jong E C
Abstract excerpt
Type I IFNs (IFNalpha/beta) are approved for the treatment of a variety of diseases, including the autoimmune disease multiple sclerosis (MS). The proinflammatory cytokines IL-12 and IFN-gamma have been proposed to contribute to the pathogenesis of MS. Since dendritic cells (DCs) are recognized a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.